Found Description
About us GRANITE BIO is a private biotechnology company located in Basel (Switzerland). It is supported by top‑tier investors with approximately $100M raised to date. Building on fundamental research conducted over the last two decades, GRANITE BIO pursues a differentiated approach to transform inflammatory, autoimmune and fibrotic conditions. Both programs are first‑in‑class monoclonal antibodies for large market opportunities in Immunology and Inflammation. GRT‑001, the lead asset, depletes inflammatory monocytes and has completed a Phase 1a trial in healthy volunteers with favorable safety and pharmacodynamic effects; a Phase 1b trial in patients with Ulcerative Colitis has just started. GRT‑002 is an IL‑3 neutralising antibody thought to play an important role in type II inflammation. The company fosters an open, inter‑disciplinary, diverse, international and creative working environment and enables work‑from‑home options according to its internal workflows. Candidates will be high...